StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Repligen's EV/EBITDA was 62.3× on Nov 11, 2026, against 113.9× a year earlier. Over the last 5 years it ranged from 28.7× to 236.6×, with a median of 61.7×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202662.3×−46.4
2025Dec 31, 2025108.7×+17.5
2024Dec 31, 202491.2×+29.5
2023Dec 29, 202361.7×+27.9
2022Dec 30, 202233.8×−43.1
2021Dec 31, 202177.0×−36.5
2020Dec 31, 2020113.5×+38.0
2019Dec 31, 201975.5×+18.6
2018Dec 31, 201856.9×−9.1
2017Dec 29, 201766.0×+20.6
2016Dec 30, 201645.4×−6.9
2015Dec 31, 201552.3×+21.1
2014Dec 31, 201431.2×−254.8
2013Dec 31, 2013286.0×+175.3
2012Dec 31, 2012110.6×+66.6
2011Dec 30, 201144.1×–

More Repligen figures

See a number that looks wrong?